Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination.
Whether differences in diet composition may influence demyelinating diseases remains controversial. The aim of this study was to analyse if diets with a different composition of polyunsaturated fatty acids (PUFAs) could influence demyelination and remyelination in cuprizone fed mice, a widely used animal model for de- and remyelination. C57Bl/6 mice were fed with 0.2% cuprizone on three different diets. The diets consisted of the same ingredients, except the lipid source, which came from 1) salmon fillets rich in marine n-3 polyunsaturated fatty acids (PUFAs), 2) cod liver oil rich in marine n-3 PUFAs, or 3) a control diet containing soybean oil rich in n-6 PUFAs. After 5 weeks of cuprizone treatment, the mice given salmon-cuprizone had significantly less hyperintense lesion volume on brain magnetic resonance imaging (MRI) than the two other groups (P<0.0005). After 6 weeks of cuprizone treatment, the salmon-cuprizone group had less demyelination in the corpus callosum, as measured with luxol fast blue (LFB) (P<0.0005) and anti-proteolipid protein (PLP) (P=0.014). The salmon-cuprizone group also had enhanced remyelination compared to the cod liver oil-cuprizone group (LFB; P=0.003, PLP; P=0.018). This study indicates that a fish rich diet may offer a protective role in demyelination. The source of N-3 PUFAs, or other components in the fish, may be important, as no effect of a cod liver oil based diet was observed. This may be of importance related to the discrepant results in dietary intervention studies for demyelinating diseases.
Torkildsen
Øivind
Ø
Norwegian Multiple Sclerosis Competence Centre, Department of Neurology, Haukeland University Hospital, N-5021 Bergen, Norway. oivind.torkildsen@gmail.com
Brunborg
Linn Anne
LA
Thorsen
Frits
F
Mørk
Sverre Jarl
SJ
Stangel
Martin
M
Myhr
Kjell-Morten
KM
Bø
Lars
L
D000818:Animals; D000943:Antigens, Differentiation / Q000378:metabolism; D003337:Corpus Callosum / Q000473:pathology / Q000503:physiopathology; D003471:Cuprizone; D003711:Demyelinating Diseases / Q000139:chemically induced* / Q000178:diet therapy* / Q000473:pathology; D004195:Disease Models, Animal; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage*; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D007211:Indoles; D007275:Injections, Intravenous / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods; D051379:Mice; D008810:Mice, Inbred C57BL; D018991:Myelin Proteolipid Protein / Q000378:metabolism; D020127:Recovery of Function / Q000502:physiology; D018709:Statistics, Nonparametric
D000943:Antigens, Differentiation; D005231:Fatty Acids, Unsaturated; D005904:Glial Fibrillary Acidic Protein; D007211:Indoles; D018991:Myelin Proteolipid Protein; C047516:Plp1 protein, mouse; C036763:monocyte-macrophage differentiation antigen; C018588:Luxol Fast Blue MBS; D003471:Cuprizone